Virbac reported first-half 2026 revenue of €768 million, representing organic growth of 7.4% at constant exchange rates and scope compared to the same period last year. The performance was driven by double-digit growth in the company's Supercharge platforms, which rose around 12% excluding the Thyronorm acquisition, while the Thyronorm deal contributed 1.4 percentage points to overall growth. Companion animal sales grew 10.0% and farm animal sales increased 6.7%, with North America delivering 10.1% organic growth despite temporary toll manufacturing and supply challenges, and Europe and International regions posting solid increases of 6.5% and 7.5% respectively. Based on the strong first half, Virbac confirmed its full-year 2026 guidance and now expects to reach the upper end of its revenue growth range of 5.5% to 7.5% at constant rates and scope, with an adjusted recurring operating income margin of around 17%.
Virbac SAVirbac reported 7.4% organic revenue growth and expects to reach upper end of guidance, with margin around 17%.